{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:49:03Z","timestamp":1781758143641,"version":"3.54.5"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2018,10,1]]},"DOI":"10.1001\/jamadermatol.2018.1165","type":"journal-article","created":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T12:31:17Z","timestamp":1528288277000},"page":"1137","source":"Crossref","is-referenced-by-count":52,"title":["Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials"],"prefix":"10.1001","volume":"154","author":[{"given":"Kristina","family":"Callis Duffin","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Dermatology, Brigham and Women\u2019s Hospital Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Rheumatology, Department of Medicine, Brigham and Women\u2019s Hospital Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[{"name":"Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen F, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Latella","sequence":"additional","affiliation":[{"name":"International Dermatology Outcome Measures Board of Directors, Windsor, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, New Hyde Park, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Department of Dermatology, New York Medical College, Metropolitan Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Keck School of Medicine of University of Southern California, Los Angeles"},{"name":"Clinical Evidence Synopsis Editor and Editorial Board Member, JAMA Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"doi180020r1","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/jid.2009.391","article-title":"How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review.","volume":"130","author":"Spuls","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"8","key":"doi180020r2","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.3899\/jrheum.130456","article-title":"Psoriasis outcome measures: a report from the GRAPPA 2012 annual meeting.","volume":"40","author":"Gottlieb","year":"2013","journal-title":"J Rheumatol"},{"issue":"6","key":"doi180020r3","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3899\/jrheum.140176","article-title":"The International Dermatology Outcome Measures initiative as applied to psoriatic disease outcomes: a report from the GRAPPA 2013 meeting.","volume":"41","author":"Gottlieb","year":"2014","journal-title":"J Rheumatol"},{"issue":"2","key":"doi180020r4","first-page":"198","article-title":"The OMERACT filter for Outcome Measures in Rheumatology.","volume":"25","author":"Boers","year":"1998","journal-title":"J Rheumatol"},{"key":"doi180020r5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13063-017-1978-4","article-title":"The COMET Handbook: version 1.0.","volume":"18","author":"Williamson","year":"2017","journal-title":"Trials"},{"issue":"6","key":"doi180020r6","doi-asserted-by":"publisher","first-page":"e002709","DOI":"10.1136\/bmjopen-2013-002709","article-title":"Selective reporting of outcomes in randomised controlled trials in systematic reviews of cystic fibrosis.","volume":"3","author":"Dwan","year":"2013","journal-title":"BMJ Open"},{"key":"doi180020r7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1745-6215-14-21","article-title":"Can a core outcome set improve the quality of systematic reviews?\u2014a survey of the Co-ordinating Editors of Cochrane review groups.","volume":"14","author":"Kirkham","year":"2013","journal-title":"Trials"},{"issue":"4","key":"doi180020r8","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1371\/journal.pmed.0050096","article-title":"A systematic review of studies that aim to determine which outcomes to measure in clinical trials in children.","volume":"5","author":"Sinha","year":"2008","journal-title":"PLoS Med"},{"issue":"2","key":"doi180020r9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/bjd.14337","article-title":"Report from the kick-off meeting of the Cochrane Skin Group Core Outcome Set Initiative (CSG-COUSIN).","volume":"174","author":"Schmitt","year":"2016","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi180020r10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/jid.2014.320","article-title":"The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology.","volume":"135","author":"Schmitt","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi180020r12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jaad.2014.11.002","article-title":"The International Dermatology Outcome Measures Group: formation of patient-centered outcome measures in dermatology.","volume":"72","author":"Gottlieb","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi180020r13","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3899\/jrheum.160114","article-title":"International Dermatology Outcome Measures initiative as applied to psoriatic disease outcomes: an update.","volume":"43","author":"Merola","year":"2016","journal-title":"J Rheumatol"},{"issue":"2","key":"doi180020r14","first-page":"119","article-title":"The International Dermatology Outcome Measures (IDEOM) initiative: a review and update.","volume":"16","author":"Elman","year":"2017","journal-title":"J Drugs Dermatol"},{"issue":"7","key":"doi180020r15","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jclinepi.2013.11.013","article-title":"Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0.","volume":"67","author":"Boers","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"doi180020r16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jaad.2011.01.022","article-title":"Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? a systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.","volume":"66","author":"Robinson","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi180020r17","doi-asserted-by":"publisher","first-page":"500","DOI":"10.2174\/138161282004140213123505","article-title":"Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review.","volume":"20","author":"Armstrong","year":"2014","journal-title":"Curr Pharm Des"},{"issue":"5","key":"doi180020r19","first-page":"641","article-title":"The Psoriatic Disease Payer Advisory Panel.","volume":"15","author":"Greb","year":"2016","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"doi180020r20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1590\/bjpt-rbf.2014.0143","article-title":"The COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) and how to select an outcome measurement instrument.","volume":"20","author":"Mokkink","year":"2016","journal-title":"Braz J Phys Ther"},{"key":"doi180020r11","unstructured":"BoersM, KirwanJR, TugwellP, . The OMERACT Handbook. Updated January 19, 2018. https:\/\/omeract.org. Accessed May 1, 2018."},{"key":"doi180020r18","unstructured":"US National Library of Medicine, ClinicalTrials.gov. Vascular inflammation in psoriasis trial. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01553058. Published March 13, 2012. Accessed September 1, 2017."}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/edhub.ama-assn.org\/journals\/jamadermatology\/fullarticle\/2681833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T16:12:57Z","timestamp":1539187977000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2018.1165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.1165","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10,1]]}}}